Navigation Links
AAPM statement on DEA ruling allowing multiple prescriptions for controlled substances
Date:11/19/2007

GLENVIEW, Ill. The American Academy of Pain Medicine (AAPM) supports todays Drug Enforcement Administration (DEA) ruling, which allows multiple prescriptions for controlled substances when appropriate. This DEA Final Ruling, Issuance of Multiple Prescriptions for Schedule II Controlled Substances, was published in the Federal Register on Monday, Nov. 19, 2007.

AAPM considers this ruling to be a positive indication of recently improved communication between the medical community and law enforcement. Under protest from pain physicians, the DEA had previously disallowed Do Not Fill Until prescriptions for several years. The agencys Final Rule has been eagerly awaited by these concerned physicians who must provide legitimate pain control.

Although not in effect until 30 days from the date of the final ruling on Issuance of Multiple Prescriptions for Schedule II Controlled Substances, this rule change allows physicians to write three separate prescriptions with staggered fill dates. Patients can still be given the equivalent of a 90-day prescription for schedule II controlled substances when medically appropriate. Schedule II drugs are those that have recognized medical uses as well as a potential for dependence and abuse. Consequently, these drugs are carefully controlled and regulated by the DEA.

This welcome policy reversal by the DEA has eliminated the burden previously imposed on patients with cancer or chronic pain who were forced to visit their physician every month for new pain medicine prescriptions when there was no medical necessity to do so. The DEA now allows physicians to use their professional judgment to carefully control the amount of a controlled substance issued to a patient at one time. Do Not Fill Until prescriptions offer increased control, safety and convenience, and may be issued in small increments for at-risk patients, or by the month to comply with insurance reimbursement regulations.

With todays Final Rule, the DEA has recognized the need for policies that support effective control of potentially abusable drugs that do not unnecessarily hinder the appropriate treatment of pain. On behalf of all legitimate patients with pain, AAPM continues to address and debate policies that address the dual crises of prescription drug abuse and undertreated pain. AAPM is committed to safe and effective treatment of pain and to effective policy on prescription drug abuse.


'/>"/>

Contact: Amy Jenkins
amy@jenkinspr.com
312-371-8365
American Academy of Pain Medicine
Source:Eurekalert

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... ... 20, 2017 , ... Researchers at the University of Pittsburgh School of Medicine ... that may predict response to a particular class of drugs, not just in patients ... The new findings were published in Proceedings of the National Academy of Science. , ...
(Date:2/20/2017)... ... 2017 , ... The StayWell Company and VUCA Health ... health risks, foster behavior change and improve health literacy among patients. VUCA Health, which ... demonstration of its video capability at StayWell booth 3443 during HiMSS. , The ...
(Date:2/20/2017)... ... February 20, 2017 , ... Sensogram Technologies Inc., the world ... visit this week at HIMSS 2017 Conference & Exhibition. The event brings more ... will be featured in the conference’s Connected Health Experience section, an area specifically ...
(Date:2/20/2017)... ... ... a Population Health Software Company, is pleased to announce a move to a larger office ... the size of the previous location while bringing life back to a medical practice building ... are excited to expand our footprint to better serve our growing client base. We ...
(Date:2/20/2017)... ... February 20, 2017 , ... Johns Hopkins All Children's Hospital ... A topping out ceremony on Friday marked the halfway point of construction and lifting ... in Fall 2018, will serve as a center for innovation aimed at finding new ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... Feb. 20, 2017  This report analyzes the worldwide markets ... Million. The report provides separate comprehensive analytics for the ... , Europe , ... and Rest of World. Read the ... and forecasts are provided for the period 2015 through ...
(Date:2/20/2017)... Feb. 20, 2017 Research and Markets has ... Insights, Opportunity, Analysis, Market Shares & Forecast 2017 - 2022" ... ... nearly USD 2 Billion by the year end of 2022 growing ... Market growth can be attributed to factors such as ...
(Date:2/20/2017)... -- Seal Shield LLC ( Jacksonville, FL ... management and disinfection, the ElectroClave™, to the exhibit floor ... Orlando, Fla. from February 20-23, 2017 ... commonplace in today,s healthcare landscape, but with this progression ... the disinfection and tracking of these devices.  The ElectroClave™ ...
Breaking Medicine Technology: